[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dementia-mild\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dementia-mild":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,49,82,113,144,168,191,219,249,275,297],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100560973","buddy-up-dyadic-physical-activity-program-for-persons-with-dementia-and-family-caregivers-100560973",false,"NCT06584110","Buddy-Up Dyadic Physical Activity Program for Persons With Dementia and Family Caregivers","Effects of Buddy-Up Dyadic Physical Activity Program on Health Outcomes and Social Dynamic of Persons With Dementia and Family Caregivers: A Mixed Method Randomized Controlled Trial","BUDPA","Eligibility for person with dementia (PwD) includes i) a confirmed diagnosis of dementia and ii) an HK-MoCA score of 8-19 to indicate mild to early moderate dementia.\n\nThe caregivers will have to i) live with the participant with dementia ii) self-identify as the primary family caregiver iii) providing care for ≥ 4 hours\u002Fday iv) has a smartphone for FaceTime\n\nThe exclusion criteria are i) engaging in ≥60 min\u002Fweek of moderate or vigorous exercise in the past six months ii) having acute muscular-skeletal problems, cerebro-cardio-respiratory disease or condition contradictory to exercise training","ALL","18 Years",{"count":20,"type":21},236,"ESTIMATED","INTERVENTIONAL",[24],"NA","The global cost of dementia is over 818 billion, and a further rise is expected in the next decade. While family caregiving is the backbone of the formal care service, promoting \"living well with dementia\" needs to extend to a dyadic perspective to address the needs of persons with dementia (PwD) and their caregivers. Unique to dementia caregiving, imbalanced exchange in the assistance, interaction, relationship and autonomy between the partners in a care dyad always challenges their social interaction and relationships. Such eroding dyadic dynamics not only worsens the mental health of caregivers, but also compromises the quality of caregiving, fosters more dementia deterioration, and eventually complicates the caregiving process. Nevertheless, least attention is directed to dyadic dynamics in promoting living well with dementia. Partner exercise is designed in a way which requires collaboration of two members to enable the workout of each other. In addition to the benefits of exercise on dementia symptom control and caregiver's stress management, partner exercise provides a meaningful encounter to encourage reciprocity, collaboration and relationship closeness within the care dyad.\n\nThis is a sequential mixed-method study including a multicenter RCT to evaluate the effects of the 16-week enhanced BUDPA and a descriptive qualitative study to explore the care dyad's overall engagement experience and perceptions. The study will be conducted in 8 elderly community centres operated by four NGOs.\n\nThe primary aim of the study investigates the effects of a 16-week enhanced BUDPA program on the health and dyadic dynamic of the persons with dementia and their family caregivers (Objective 1-3). The secondary aim explores dyads' overall experience in program engagement, particularly in terms of perceived benefits, challenges, and experience in self-directed practice (Objective 4). The primary outcomes include PwD's cognitive function and caregivers' mood status.\n\nWe hypothesize that the 16-week enhanced BUDPA program will be more effective than usual care immediately post-test (T1: week 16) and 3 months (T2: week 29) and 6 months thereafter (T3: week 42) in:\n\n1. improving cognitive function, NPS and HRQL of persons with mild to early-moderate dementia.\n2. improving the affect, positive aspects of caregiving, and HRQL of family caregivers.\n3. improving the dyadic dynamic between the person with dementia and family caregiver in a dyad.",[27,28,29,30],"Cognitive Impairment, Mild","Dementia, Mild","Dementia","Caregiver Burden",[32,33,34,35],"dementia","dyads exercise","cognitive impairment","caregiver","RECRUITING","2026-03-31",{"date":39,"type":40},"2026-04-06","ACTUAL",{"date":42,"type":40},"2024-10-01",{"date":44,"type":21},"2027-03-30",{"name":46,"class":47},"The University of Hong Kong","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":48},"100567134","development-of-pressure-sensor-based-dementia-and-fall-prevention-program-for-older-adults-100567134","NCT06664229","Development of Pressure Sensor Based Dementia and Fall Prevention Program for Older Adults","Development of the Flexible and Printed Electronic Device for Dementia and Fall Prevention of Older Adults","Inclusion Criteria:\n\n* Older adults in the community who are 65 years old or older.\n\nExclusion Criteria:\n\n* Older adults who cannot walk independently with assisting devices or use wheelchair.\n* Older adults who are diagnosed with dementia, or other neurological\u002Fmental disorders that may limit their cognitive ability to participate in the study.\n* Older adults who cannot speak or read Korean.",true,"65 Years",{"count":59,"type":21},205,[24],"The goal of this intervention program is to test the effectiveness of pressure sensor based dementia and fall prevention program for improving cognitive and physical functions of community dwelling older adults. The main purposes of this study are:\n\n1. Develop a pressure sensor based exercise mat and linked software programs to be used for group training sessions for cognitive and balance training of older adults at a community senior center.\n2. Evaluate efficacy of the program to improve cognitive and physical functions of older adults via a pilot study and a main study with randomized control trial design.\n\nOlder adults will be asked to participate in a group training session that was lead by a fitness coach using a pressure sensor mat, a standing monitor, and a linked software programs. They will be asked to stand on the mat, which is set in front of a monitor to show positions of the mat where they place their foots. The monitor screen will guide them to conduct either a balancing exercise for fall prevention or a cognitive exercise such as memory game or quiz game for dementia prevention.\n\nResearchers will compare age and gender matched control group in a main study to see if cognitive and balancing functions of intervention group is better than the control group by conducting pre and post surveys and physical examinations. A pilot study will examine pre-post changes in the intervention group without the control group.",[28,63,64],"Accidental Falls","Mild Cognitive Impairment",[66,67,68,69,70,71,72],"Fall prevention","Dementia prevention","Mild cognitive impairment","Exercise game","Cognitive training game","Community based intervention","Older adults","2026-03-17",{"date":75,"type":40},"2026-03-20",{"date":77,"type":40},"2024-01-15",{"date":79,"type":21},"2026-12-31",{"name":81,"class":47},"Sunmi Song",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100599335","phase-3-glp-1gcg-dual-agonist-in-type-2-diabetes-with-early-dementia-light-cog-study-100599335","NCT07083154","GLP-1\u002FGCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)","Efficacy, Safety, and Tolerability of a GLP-1\u002FGCG Dual Receptor Agonist in Type 2 Diabetes With Early Dementia: A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Type 2 diabetes mellitus (T2DM).\n2. Aged 50-75 years (inclusive), male or female.\n3. Early symptomatic dementia (Mild cognitive impairment or mild dementia), defined as:\n\n   1. MMSE score \\>20 and \\\u003C27,\n   2. CDR global score 0.5-1.0 (inclusive), with a CDR memory subscore ≥0.5,\n   3. Subjective memory complaints for ≥6 months.\n4. Stable glycemic control regimen for ≥3 months prior to screening, meeting one of the following:\n\n   1. Lifestyle\u002Fdietary intervention alone (no glucose-lowering drugs),\n   2. Oral antidiabetic drugs (OADs), with or without once-daily basal insulin.\n5. HbA1c 7.0-9.0% (inclusive) at screening.\n6. BMI ≥20 kg\u002Fm², with stable weight (fluctuation \\\u003C5%) for ≥3 months.\n7. Stable treatment regimen for cognitive impairment for at least 3 months prior to screening and commit to its continuation throughout the study period, meeting one of the following criteria:\n\n   1. No treatment: Not receiving any pharmacological or non-pharmacological interventions for cognitive impairment;\n   2. Non-pharmacological therapy only: Engaged exclusively in non-drug interventions (e.g., cognitive training);\n   3. Pharmacological therapy: Using approved symptomatic cognitive-enhancing medications (e.g., cholinesterase inhibitors, NMDA receptor antagonists), excluding disease-modifying therapies for Alzheimer's disease (AD).\n8. Ability to comply with systematic cognitive and functional assessments.\n9. Fully understands the trial protocol, voluntarily signs the informed consent form (ICF), and agrees to adhere to all study requirements and restrictions.\n\nExclusion Criteria:\n\n1. Evidence of other neurodegenerative diseases that may affect cognition, excluding Alzheimer's disease, including:\n\n   1. Frontotemporal dementia (FTD) and its variants\n   2. Parkinson's disease (PD), dementia with Lewy bodies (DLB)\n   3. Progressive supranuclear palsy (PSP), corticobasal degeneration (CBD)\n   4. Multiple system atrophy (MSA), multiple sclerosis (MS), Huntington's disease (HD), etc.\n2. Current diagnosis of a poorly controlled or unstable psychiatric disorder (including but not limited to schizophrenia, bipolar disorder, major depressive disorder, generalized anxiety disorder, personality disorders, etc.), which, in the investigator's judgment, may interfere with study assessments, affect treatment compliance, or increase participant risk.\n3. With a Patient Health Questionnaire-9 (PHQ-9) score ≥10 at screening, or a Generalized Anxiety Disorder Scale-7 (GAD-7) score ≥10 at screening.\n4. History of stroke (ischemic\u002Fhemorrhagic), transient ischemic attack (TIA), or epileptic seizure within 3 months prior to screening; Current or prior diagnosis of central nervous system (CNS) disorders that may impair cognitive function, including but not limited to:\n\n   CNS infections, Intracranial tumors, Metabolic encephalopathy, Neurological disorders due to malnutrition, or Severe traumatic brain injury.\n5. Acute hyperglycemic\u002Fhypoglycemic events within 1 year, including: Diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), and Hypoglycemic coma\n6. Use of GLP-1R agonists, GLP-1R\u002FGIPR dual agonists, or GLP-1R\u002FGCGR dual agonists within 3 months prior to screening.\n7. Regular use (\\>2 doses\u002Fweek) of moderate-to-strong anticholinergic drugs within 4 weeks prior to screening; Use within 3 months prior to screening of: Anti-Parkinsonian drugs, Antiepileptic drugs, Antipsychotics, Morphine and opioid analgesics (Exemption: Short-term use \\[\\\u003C5 days\\] for surgery\u002Facute injury, if completed \\>4 weeks before screening); Use within 4 weeks prior to screening of: CNS stimulants; Medical\u002Frecreational cannabis, cannabinoids, or cannabidiol (CBD).a. Moderate\u002Fhigh anticholinergics, antiparkinsonian\u002Fantiepileptic drugs.\n8. Alcohol abuse (defined as \\>21 units\u002Fweek for men or \\>14 units\u002Fweek for women; 1 unit = 360 mL beer, 150 mL wine, or 45 mL spirits).\n9. Medical history of:\n\n   1. Medullary thyroid carcinoma (MTC), pancreatitis\n   2. Multiple endocrine neoplasia type 2 (MEN2)\n   3. Gallbladder\u002Fbiliary disease, severe gastrointestinal disorders, or bowel resection\n   4. Active malignancy\n10. Uncontrolled or potentially unstable diabetic retinopathy\u002Fmaculopathy.\n11. Severe organ dysfunction, including:\n\n    1. ALT\u002FAST \\>3× upper limit of normal (ULN)\n    2. eGFR \\\u003C45 mL\u002Fmin\u002F1.73m² (CKD-EPI equation)\n    3. Unstable angina, myocardial infarction (MI), or NYHA Class II+ heart failure within 3 months\n12. Known\u002Fsuspected hypersensitivity to the investigational product or related compounds\n13. Pregnancy, lactation, or women of childbearing potential not using highly effective contraception.\n14. MRI contraindications (e.g., metal implants, claustrophobia).\n15. Participation in other clinical trials within 3 months, involving an investigational medicinal product or enrollment in any other type of medical research judged not to be scientifically or medically compatible with this study.\n16. Any other condition deemed by the investigator to compromise safety or interfere with study assessments.","50 Years","75 Years",{"count":92,"type":21},420,[94],"PHASE3","The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. A total of 420 type 2 diabetes patients with early dementia are randomized 1:1 to either the active treatment group (receiving subcutaneous injections of mazdutide weekly, with stepwise dose escalation to a maintenance dose per protocol) or the placebo group (receiving matched placebo injections). The primary objective is to evaluate the potential disease-modifying effects of mazdutide on cognitive dysfunction in type 2 diabetes.",[28,64,97],"Type 2 Diabetes",[97,99,64,100,101,102],"Mild Dementia","GLP-1\u002FGCG Dual Agonist","Cognitive Dysfunction","Early Dementia","2026-03-03",{"date":105,"type":40},"2026-03-05",{"date":107,"type":40},"2025-09-27",{"date":109,"type":21},"2029-08-01",{"name":111,"class":47},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",8,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":56,"sex":17,"minAge":119,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100587431","cognitive-screening-made-easy-for-pcps---administrative-supplement-100587431","NCT06928298","Cognitive Screening Made Easy for PCPs - Administrative Supplement","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Aged 60 years and older;\n* Ethnic\u002Fracial background consistent with NIH policy\n* Male or female\n* Fluent in Spanish.\n\nExclusion Criteria:\n\n* Confounding conditions that could impact ability to participate in the study (e.g., cognitive impairment sufficient to impact ability to follow instructions on the iPad, motor impairment that would prohibit independent use of RACS, poor visual acuity)\n* Prior diagnosis of dementia\n* Non-Spanish speaking.","60 Years",{"count":121,"type":21},100,[24],"This project will facilitate early detection of cognitive decline in older adults through development and implementation of an automated risk assessment and cognitive screening tool for use in primary care. By providing an automated tool developed specifically to address the needs of PCPs, it will be easier to screen for cognitive impairment, increasing the number of older adults who are screened and thus identified and treated.",[125,126,28],"Cognitive Impairment","Cognitive Decline",[128,129,130,131,132,133],"older adults","mild cognitive impairment","mild dementia","cognitive screening","primary care","dementia screening","2026-02-02",{"date":136,"type":40},"2026-02-05",{"date":138,"type":40},"2025-06-10",{"date":140,"type":21},"2027-04-30",{"name":142,"class":47},"University of Texas at Austin",3,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":56,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":48},"100581777","pain-with-dementia-100581777","NCT06854718","Pain With Dementia","Caregiver-assisted Pain Coping Skills Training for Dementia Pilot Study","PWD","Inclusion Criteria:\n\nPatients:\n\n* Mild or moderate dementia\n* Pain on most days for at least 3 months that interferes with function\n* Living at home (non-institutional)\n* Age ≥ 50\n* English Speaking\n\nCaregivers:\n\n* Provides on average at least 4 hours\u002Fday of care\u002Fassistance to the patient\n* Age ≥ 18\n* English Speaking\n\nExclusion Criteria:\n\nPatient and caregivers\n\n* Lacking capacity for interview or unable to provide informed consent\u002Fassent.\n* Visual or hearing impairments or severe behavioral problems that preclude participation.\n* Too sick to participate.",{"count":153,"type":21},60,[24],"The purpose of the study is to develop a caregiver-assisted pain coping skills training program for older adults who have pain and mild to moderate dementia and are living at home with a family caregiver. The investigators are planning to recruit 30 patient-caregiver dyads (60 individuals).",[157,28,158],"Pain","Dementia, Moderate","2025-12-02",{"date":161,"type":40},"2025-12-03",{"date":163,"type":40},"2025-08-13",{"date":165,"type":21},"2026-12-01",{"name":167,"class":47},"Duke University",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":48},"100538584","autonomic-involvement-in-patient-with-cognitive-decline-100538584","NCT06292741","Autonomic Involvement in Patient With Cognitive Decline","Evaluation of the Prevalence of Autonomic Nervous System Involvement in Patients With Cognitive Impairment by a Non-invasive Combined Study of Dysautonomia","Inclusion Criteria:\n\n* male and females between 50 and 85 years\n* cognitive decline (dementia, lewy's body dementia, Parkinson dementia, Alzheimer dementia)\n* mild cognitive decline ( lewy's body MCI, Parkinson MCI and Alzheimer MCI)\n* Ability to assume the upright position\n\nExclusion Criteria:\n\n* diabetes mellitus\n* eye problems\n* severe cognitive decline\n* heart disease\n* peripheral neuropathy\n* language barrier\n* oncological disease\n* medical pathologies associated with cognitive deficits","85 Years",{"count":177,"type":21},120,[24],"Prospective interventional study with a device for comparing autonomic parameters among patients with different forms of cognitive decline",[28,181],"Dementia of Alzheimer Type","2025-08-25",{"date":184,"type":40},"2025-08-26",{"date":186,"type":40},"2023-01-11",{"date":188,"type":21},"2026-01",{"name":190,"class":47},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":48},"100578886","the-lets-talk-tech-tool-to-support-decision-making-about-technology-use-100578886","NCT06817122","The \"Let's Talk Tech\" Tool to Support Decision Making About Technology Use","Mechanistic Study of the \"Let's Talk Tech\" Dyadic Behavioral Intervention to Support Decision Making About Technology Use","Inclusion Criteria for Patients:\n\n* have mild cognitive impairment (MCI) or mild dementia\n* age 55 or older\n* able to understand and speak English\n\nInclusion Criteria for Co-participants:\n\n* be identified by the patient as their primary support person\n* age 18 or older\n* able to understand and speak English\n* able to complete LTT together with their study partner at the same time\n\nExclusion Criteria:\n\n* None",{"count":199,"type":21},240,[24],"The goal of this research is to educate people about different technologies to support care at home when someone is experiencing memory difficulties. \"Let's Talk Tech\" is a new tool to educate people about technologies commonly used to support care and monitor safety, and help families talk about their feelings about them to understand each other's perspectives. The goal of this clinical trial is to learn if \"Let's Talk Tech\" helps people feel more prepared to make decisions about technologies.\n\nResearchers will compare Let's Talk Tech to usual care (no intervention) to see if Let's Talk Tech increases peoples' preparedness and confidence to make decisions about technologies.\n\nParticipants will:\n\n* Use the Let's Talk Tech web application together with their study partner that takes up to an hour or do nothing.\n* Complete three surveys. The second survey will be taken within 2 weeks of the first and the last survey will be taken 3 months after the first.",[28,203],"Mild Cognitive Impairment (MCI)",[205,206,207,208,209],"Let's Talk Tech","shared decision aid","technology decision making","advance care planning","dyadic intervention","2025-03-24",{"date":212,"type":40},"2025-03-25",{"date":214,"type":40},"2025-02-07",{"date":216,"type":21},"2026-04",{"name":218,"class":47},"University of Washington",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":119,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":234,"overallStatus":239,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":48},"100536402","developing-a-nonpharmacological-pain-intervention-for-community-dwelling-older-adults-with-dementia-100536402","NCT06264362","Developing a Nonpharmacological Pain Intervention for Community-dwelling Older Adults With Dementia","Inclusion Criteria for people living with dementia:\n\n* Age 60 or older\n* Speaks English\n* Mild\u002FVery Mild dementia\n* Knee pain lasting ≥ 3 months, potentially related to arthritis\n* Knee pain is at least 2 out of 10 on average.\n\nExclusion Criteria for people living with dementia:\n\n* Reside in long term care facility\n* Unable or unwilling to consent\n* Has a condition with a life expectancy of less than 1-year\n* No care partner who is also willing to participate\n* Recent changes to pain or psychotropic medications in the last 60 days\n* Recent knee surgery in the last 1-year\n* Has a condition that contraindicates exercise (Phase 2 only)\n* Currently receiving rehab services (Phase 2 only)\n\nFor care partners:\n\n* No sex, gender, or age criteria\n* Has known person living with dementia ≥ 1 year\n* Speaks English\n* Able and willing to consent, including being recorded\n\nFor clinicians:\n\n* No sex, gender, or age criteria\n* Speaks English\n* Has ≥ 2 years of experience working with community-dwelling people with dementia and pain\n* Able and willing to consent, including being recorded",{"count":226,"type":21},40,[24],"The purpose of this study is to develop an exercise treatment program for knee osteoarthritis that works well for people with memory problems. This study will include two parts. Participants can choose to participate in either or both parts.\n\nIn Part 1 (not a clinical trial) - The investigators are inviting the following people to participate in an interview:\n\n1. Individuals aged 60 years or older who do not live in a nursing home and have both memory issues and knee pain.\n2. Care partners of people with knee pain and memory issues. A care partner can be a family member or friend who helps regularly.\n3. Clinicians (exercise physiologists or rehabilitation therapists like physical and occupational therapists) who have worked with older adults with memory issues and knee pain.\n\nThe goal of these interviews is to learn from the experiences of people with memory issues and knee pain and those who care for them. From these interviews, the investigators hope to design a non-drug, tailored physical activity program that will be interesting and helpful in managing knee pain for older adults with memory problems.\n\nFor people with memory problems and knee pain and their care partners: The investigators will ask some questions to determine eligibility to participate in the study.\n\nThose who qualify for the study will be invited to participate in an interview that could be completed online or in person (Philadelphia, PA). The interview could last up to 90 minutes (1 and a half hours) and can be completed as one or multiple sessions.\n\nFor clinicians: Participants will engage in a 90-minute focus group with other clinicians where lunch will be served if in person. Those participating in an online focus group will receive a gift card equal to the value of lunch.\n\nIn Part 2 (a clinical trial) - The program developed in Part 1 will be tested. The program will be physical activity-based. Specific program details for part 2 will be provided as they emerge. Participants can choose to sign up for either or both parts. Signing up for Part 1 does not mean participants have to sign up for Part 2.\n\nPlease contact us for any questions.",[230,28,231,232,233,64],"Pain, Chronic","Mobility Limitation","Physical Disability","Osteo Arthritis Knee",[235,32,34,236,237,238],"pain","osteoarthritis","knee pain","memory","NOT_YET_RECRUITING","2025-03-10",{"date":242,"type":40},"2025-03-11",{"date":244,"type":21},"2025-06-02",{"date":246,"type":21},"2027-05-01",{"name":248,"class":47},"Drexel University",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":259,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":48},"100551059","eerder-erbij-the-path-towards-offering-timely-support-for-people-with-dementia-and-their-caregivers-100551059","NCT06455163","Eerder Erbij: The Path Towards Offering Timely Support for People With Dementia and Their Caregivers","Eerder Erbij: Een Vroege Ondersteuning Voor Mensen Met Dementie en Hun Mantelzorgers. The Path Towards Offering Timely Support for People With Dementia and Their Caregivers","EE","Inclusion Criteria:\n\n* Informal caregivers can be spouses, relatives, or friends who care for and support the person with dementia without pay. If the caregiver does not live with the person with dementia, they have to visit the person with dementia at least 3 times a week to be eligible for the study.\n* The person with dementia must be living at home cared for by the caregiver.\n* The person with dementia should have a diagnosis of dementia or experience severe cognitive impairments suggesting dementia. Type of dementia is not an inclusion criterion.\n* The person with dementia is not yet receiving formal care related to personal activities of daily living on account of his or her dementia more than once a week (defined by receiving assistance from a paid worker by e.g., health or social care professional as help with dressing\u002Fundressing; washing\u002Fbathing\u002Fshowering; toileting; feeding\u002Fdrinking; or taking medication).\n\nExclusion Criteria:\n\n* Main exclusion criteria for both the caregiver and the person with dementia will be major mental or physical illness, such as major depression or stroke, that would affect their ability to participate in this study.\n* Person with dementia or informal caregiver is participating in another intervention or similar support program.\n* Dementia is caused by human immunodeficiency virus (HIV), acquired brain impairment, Down syndrome, chorea associated with Huntington's disease, or alcohol abuse.\n* Inability to give informed consent will also be an exclusion criterion.\n* Informal caregiver is younger than 18 years old.",{"count":258,"type":21},102,[24],"INTRODUCTION AND RATIONALE\n\nIt has been estimated that at least 50% of the home living persons with dementia in the Netherlands receive little or no formal care and support (Zorgstandaard Dementie, 2013). Reasons why persons with dementia and their informal caregivers receive no formal care vary, include absence of diagnosis, denial of illness, embarrassment or the complexity of the care and referral system. A common concern among health care professionals is that by the time the person with dementia or informal caregiver do seek or receive formal care it may be too late. The difficulties at home may already be so severe that there is little that community-based care can do and admission to residential care may follow soon after. Appropriate support at an earlier stage may prevent more serious difficulties and postpone admission to residential care. Therefore, health care professionals are looking for strategies to reach persons with dementia and caregivers in an earlier stage of dementia and encourage them to accept some form of help or support. The rationale of this study is to investigate how persons living with dementia and their close others can be encouraged to accept support and whether support at an early stage is effective in preventing severe deterioration in wellbeing, behavioural difficulties and high care costs later on.\n\nOBJECTIVES\n\n* Estimate the effect of EE on caregiver self-efficacy compared to usual care\n* Estimate the effect of EE on the total care costs of caregiver and person with dementia compared to usual care\n* Estimate the cost-effectiveness and cost-utility of EE compared to usual care\n* Perform a process evaluation to monitor delivery of EE and experiences of persons with dementia, caregivers and care professionals\n* Explore treatment responsiveness of EE in terms of self-efficacy and quality of life\n\nSTUDY DESIGN\n\nPragmatic, cluster randomised controlled trial.\n\nSTUDY POPULATION\n\nInformal caregivers and people with early-stage dementia, who are community dwelling and receive little or no dementia-related formal ADL care.\n\nINTERVENTION\n\nThe intervention (Eerder Erbij, EE) is a person-centred, manual-based intervention consisting of education, information and a support group.\n\nMAIN STUDY PARAMETERS\u002FENDPOINTS\n\nPrimary: self-efficacy. Cost-utility: EQ5D, RUD. Secondary: quality-of-life, caregiver burden.\n\nDATA COLLECTION\n\nMeasurements consist of questionnaires (total duration is approximately 1 hour; administered at home; take place at baseline, 3, 6, and 12 months).",[28],[263,264,265],"Early-stage dementia","Informal caregiver","Informal care","2024-08-13",{"date":268,"type":40},"2024-08-15",{"date":270,"type":40},"2021-06-01",{"date":272,"type":21},"2026-05-31",{"name":274,"class":47},"VU University of Amsterdam",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":143},"100550266","paper-based-and-smartphone-based-memory-supports-100550266","NCT06444841","Paper-Based and Smartphone-Based Memory Supports","Smartphone-Based Solutions for Prospective Memory in Mild Cognitive Impairment and Dementia","Inclusion Criteria:\n\n* Demonstrate capacity to consent via structured interview that involves reviewing core study features and probing for understanding of potential benefits\u002Fconsequences of participating, and understanding that one can withdraw consent at any point, or availability to obtain surrogate consent.\n* Clinical features consistent with a diagnosis of MCI or dementia. For clinic-referred participants, available records will be reviewed to ensure the clinical diagnosis meets published diagnostic guidelines. If there is not sufficient documentation for diagnostic purposes, then semi-structured clinical interview and cognitive screening (see below) will be reviewed by clinical staff.\n* Cognitive status for inclusion will be assessed by Montreal Cognitive Assessment (MoCA) scores of 17-25 (or 12-18 for the telephone version if in-clinic assessment is not feasible). While some studies suggested that these ranges are appropriate across diverse groups, recent work indicates that adjustment of 1-2 points for different demographics improves instrument sensitivity in disadvantaged groups. The latter approach will be taken.\n* Functional status will be assessed via semi-structured interview with the Global Deterioration Scale (GDS), with stage 3 or 4 indicating independence in basic self-maintenance activities.\n* Adequate sensory and motor abilities to utilize a smartphone with accommodation.\n* Availability of a co-participant who sees the participant at least once a month.\n\nCo-Participant Inclusion Criteria:\n\n* The co-participant will need to be over the age of 18, consent to participation, and see the participant at least once per month.\n\nExclusion Criteria:\n\n* History of serious mental illness including schizophrenia or bipolar disorder that is judged by the clinician to be the primary cause of cognitive decline.\n* Indication of moderate or severe dementia based on clinical documentation, MoCA score, and\u002For collateral\u002Finformant activities of daily living measure during the screening process (GDS score ≥5).\n* Language difficulties significant enough to interfere with the screening procedures.\n* Uncorrected hearing loss, vision loss, or motor dysfunction significant enough to interfere with training.\n* No study partner.\n* At the current time, individuals who do not identify as conversational in English will be excluded from participation.\n\nCo-Participant Exclusion Criteria:\n\n* Sees participant less than once per month.\n* At the current time, individuals who do not identify as conversational in English will be excluded from participation.",{"count":283,"type":21},200,[24],"Alzheimer's disease and related dementias lead to marked declines in daily functioning, independence, and quality of life. One of the earliest cognitive changes in these conditions is impairment in prospective memory, or the ability to remember future intentions such as taking medications at a given time. Prior intervention studies that targeted prospective memory used mnemonic strategies or cognitive training, but these approaches resulted in modest gains in clinical populations. By contrast, a Stage I pilot trial indicated that smartphone-based memory aids (reminder apps) can be accepted and used by persons with mild cognitive impairment and mild dementia to improve both subjective and objective prospective memory performance. The investigators will now test for efficacy, durability, and generalizability of benefits across diverse samples in a Stage II randomized controlled trial. Some 200 participants with mild cognitive impairment or mild dementia will be recruited, half of whom will be from digitally-disadvantaged backgrounds (low socioeconomic status, rural, or historically underrepresented groups). Participants will complete baseline assessments and then be randomly assigned to a smartphone reminder app intervention or an active control condition that uses a paper- based memory support system. Across a 4-week intervention period, participants will complete patient-selected and experimenter-assigned prospective memory assessments and receive booster training sessions to promote self-efficacy with the intervention\u002Fcontrol system. Durability of effects will be assessed at 3-month and 6-month follow-up sessions. As a secondary aim, study partners will be simultaneously enrolled to collect informant ratings, track how much study partners assist the participants, and determine whether improving prospective memory in patients improves quality of life in study partners (e.g., by reducing the double to-do list burden of remembering for themselves and for care recipients). As a third aim, the investigators will identify barriers and facilitators to smartphone interventions in digitally-disadvantaged individuals who have historically been underrepresented in technology and dementia research.",[287,28,64],"Alzheimer Disease","2024-07-08",{"date":290,"type":40},"2024-07-09",{"date":292,"type":40},"2024-06-27",{"date":294,"type":21},"2028-09-30",{"name":296,"class":47},"Baylor University",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":306,"phases":4,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":48},"100441071","pumch-dementia-longitudinal-cohort-study-100441071","NCT05023564","PUMCH Dementia Longitudinal Cohort Study","Peking Union Medical College Hospital (PUMCH) Dementia Longitudinal Cohort Study","Inclusion Criteria:\n\n* Neurodegenerative dementia diagnosis based on 2011 NIA-AA criteria of Dementia\n* Fixed care giver and can follow up regularly\n\nExclusion Criteria:\n\n* Not demented, including MCI\n* Systemic severe diseases and severe vision or hearing problem effecting follow up and neuropsychological evaluation\n* Without fixed care giver\n* Reject informed consent\n* Expected life shorter than 2 years",{"count":305,"type":21},20000,"OBSERVATIONAL","The PUMCH Dementia Cohort is a hospital-based, observational study of Chinese elderly with cognitive impairment.",[29,309,310,311,312,313,28],"Dementia, Vascular","Dementia With Lewy Bodies","Dementia, Mixed","Dementia Alzheimers","Dementia Frontal","2022-09-10",{"date":316,"type":40},"2022-09-13",{"date":318,"type":40},"2020-12-01",{"date":320,"type":21},"2040-12-31",{"name":322,"class":47},"Peking Union Medical College Hospital"]